Management

Under the authority of Dr. Liu Zhongyi, CEO of Lotus Pharmaceuticals, the Executive Committee coordinates the implementation of strategies for the Group and the allocation of the required resources. Management is committed to serving the interests of the entire enterprise and achieving a sustained increase in corporate value. Dr. Liu coordinates the principles of corporate policy.

The most important tasks of the Management are defining corporate strategy, setting the budget and allocating corporate resources. The Board of Directors also ensures that the shareholders receive regular, timely and comprehensive information on all matters relating to Lotus’s planning, business development and risk management.

Dr. Liu Zhong Yi

Dr. Liu Zhong Yi, Chairman, CEO & President, is the founder of Lotus Pharmaceuticals, Inc. in the United States and its Chinese antecedent, Liang Fang Pharmaceuticals Co., Ltd. in Beijing. He earned his Master’s Degree in Beijing hospitals, after doing his undergraduate studies in his homeland of Inner Mongolia. Dr. Liu holds the title of Deputy Chief Physician, as a professional apothecary, in operating Lotus (Liang Fang) as one of China’s most innovative and fastest growing pharmaceutical companies.

As a researcher and medical student, Dr. Liu excelled in the development of many new drugs in wide use in China today. While working for the Chinese Government in 1992, he established the Research Center of Space Flight Biological Engineering Technology, and continued his renowned research related to incretion diseases. Four years later, entering the private sector and invigorated by burgeoning capitalism in China, Dr. Liu started his first pharmaceutical company in Beijing.

The year 1999 marked a landmark for Dr. Liu and his company by the introduction of VALSARTAN, China’s most effective and popular drug for the treatment of hypertension. During this same period, he commenced his hugely successful retail drug stores that now number 10 throughout Greater Beijing.

In early 2006, Dr. Liu aligned his operations with Genesis Equity Partners, LLC, the U.S.-based capital investment firm. Lotus Pharmaceuticals, Inc. (OTCBB: LOTS) became a NASDAQ Bulletin Board Company when it officially commenced trading on month, day, 2006.

Adam Wasserman

Adam Wasserman, Chief Financial Officer, is a highly effective financial executive with demonstrated success in increasing the profitability and value of companies. Throughout his career he has been an integral member of executive management responsible for financial and accounting. He has a strong background in financial reporting, budgeting and planning, mergers and acquisitions, auditing, accounting, automated systems, banking relations and internal controls. Mr. Wasserman was an audit manager at American Express Tax & Business in Fort Lauderdale , Florida .

During his tenure as manager, Mr. Wasserman successfully acted as an outsourced CFO and advisor to a diversified clientele in the wholesale, technology, distribution, medical, retail, and service industries in both the private and public sector. His responsibilities included supervising, training and evaluating senior staff members, work paper review, auditing, maintaining positive client relations, preparation of tax returns and preparation of financial statements and the related footnotes. Mr. Wasserman has experience with SEC filings such as initial public offerings, 10-Ks and 10-Qs. Prior to this, Mr. Wasserman was with Deloitte & Touche, LLP in New York City . Significant assignments included audits of public (SEC reporting) and private companies, tax preparation and planning, management consulting, systems design, staff instruction, and recruiting. Mr. Wasserman holds a Bachelor of Administration from the State University at Albany in Albany , New York . He is a CPA and a member of The American Institute of Certified Public Accountants and the Florida Institute of Certified Public Accountants. On several occasions, Mr. Wasserman has traveled to China to assist companies in transforming to GAPP and SEC reporting enterprises.

Xian Wenli

Xian Wenli, Vice President, graduated from Western China Medical University. Ms. Xian has been serving as Vice President of Lotus Pharmaceuticals since 2000.

Fan Xiaohui

Fan Xiaohui, Treasurer, graduated from Inner Mongolia Financial College in 2001. Ms. Fan has been serving as the accountant for Liang Fang Pharmaceuticals since 2001.

Zhang Wenzhu

Zhang Wenzhu, Secretary, graduated from Inner Mongolia Financial College in 2001. Ms. Zhang has been serving as the secretary for Liang Fang Pharmaceuticals since 2001.

This website contains forward-looking statements that involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the company's business and financial results is included in the Company's filings, available via the United States Securities & Exchange Commission. Occasionally, the Company may select and post articles or opinions of third parties, with no known connection with the Company. These are considered expert or qualified writers about the Chinese economy and its various opportunities and pitfalls. The Company neither endorses nor rejects these views or content, and the articles are offered only for the readers' edification and personal analyses.